Morphic Therapeutic (MORF) - Price-to-Projected Revenue Ratio

Morphic Holding, Inc. - graphic logo of issuer MORF

The integration of the R&D pipeline into the structure of the Lilly behemoth has provided Morphic Holding, Inc. (MORF) with strategic growth. The forward P/S valuation metric confirms this trend, with the value stabilizing at 2674.60. The business relies on a closed patent perimeter for oral GI therapy, although financial stability currently depends directly on the outcomes of ongoing medical trials.

morphictx.com - MORF Forward Price to Sales (period 07/04/2022 - 04/26/2024)

Summary analytical data breakdowns for Morphic Holding Corp (MORF)

- market price and analyst price targets:
Price Chart Morphic|MORF - Fair Value Consensus
- market capitalization indicators:
Market Value Morphic Holding Corp|MORF - Full Business Value
- book value of equity indicators:
Book Value per Share Morphic|MORF - Accounting Value of Company|Market Capitalization to Book Value Ratio morphictx.com|MORF - Company Total Asset Base
- debt burden and liquidity indicators:
Total Debt to Capital Morphic Holding, Inc.|MORF - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Morphic Holding, Inc.|MORF - Aggregate Debt Obligations|Debts to Book Capitalization Morphic Holding Corp|MORF - Company Long-Term Loans and Borrowings|Company Short-Term Debt Morphic|Quick Liquidity morphictx.com
- financial results and valuation multiples details:
MORF - Company Net Income|Projected Future Earnings Morphic Holding, Inc.|MORF - Price to Earnings Multiple|Forward P/E Multiple Morphic Holding Inc|MORF - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic Holding Corp|MORF - Operating profit before amortization|Net earnings per share (EPS TTM) Morphic|MORF - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months morphictx.com|MORF - Earnings per share increase in current year|Earnings growth forecast for next year Morphic Holding, Inc.
- company sales and revenue statistics:
MORF - Company Gross Revenue|Company Projected Revenue Morphic|MORF - Market Cap to Revenue Ratio|Forward P/S Multiple Morphic Holding Corp
Summary company analysis:Morphic MORF
Product sample of morphictx.com

Forward P/S measures the market value of a business relative to projected revenue, allowing an investor to assess the extent of future expectations priced in and timely recognize an overbought asset. Analyzing the forward price-to-sales ratio helps filter out speculative noise by evaluating the commercialization potential of the unique MInT platform for creating convenient oral medications for ulcerative colitis therapy from Morphic Holding, Inc. (MORF).

Key competitors

Price-to-Projected Revenue Ratio Phathom Pharmaceuticals, Inc. PHAT|Forward Price to Sales TERN|IRWD - Price-to-Projected Revenue Ratio|Future Price to Revenue CURX|IMRN: Forward P/S Multiple|evokepharma.com - Forward Price to Sales|ENTO (Entero Therapeutics Inc.) - Forward P/S Multiple|RedHill (RDHL) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PALI|Forward Price-to-Revenue Multiple Jaguar Health Corp JAGX|Biora Therapeutics - Forward Price-to-Revenue Multiple